KLRG1, Another Opportunity for a Breakthrough in MTCL-Reference-Cited by-同舟云学术

KLRG1, Another Opportunity for a Breakthrough in MTCL

Published:2024-04-03 Issue:11 Volume:30 Page:2300-2302
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Varma Gaurav¹²^ORCID,Diefenbach Catherine S.¹²^ORCID

Affiliation:

1. 1Division of Hematology and Medical Oncology, Department of Medicine, NYU Grossman School of Medicine, New York, New York.

2. 2Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.

Abstract

Summary Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing mAbs compromised by limited efficacy and significant immunocompromise. Anti–killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T cells and avoid the toxicity concerns with previous agents. See related article by Assatova et al., p. 2514

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-24-0374/3439589/ccr-24-0374.pdf

Reference19 articles.

1. KLRG1 cell depletion as a novel therapeutic strategy in patients with mature T-cell lymphoma subtypes;Assatova;Clin Cancer Res,2024

2. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms;Alaggio;Leukemia,2022

3. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

4. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma;Stuver;Br J Haematol,2023

5. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA);Bachy;J Clin Oncol,2022